ATYR Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
-100.0%
190.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
-100.0%
190.0K
Operating Expenses
18.8M
+72.7%
10.9M
-4.9%
11.4M
-22.7%
14.8M
-45.1%
26.9M
R&D
10.4M
+54.8%
6.7M
-7.8%
7.3M
-32.8%
10.9M
-50.8%
22.1M
SG&A
8.3M
+102.0%
4.1M
+0.3%
4.1M
+5.5%
3.9M
-18.7%
4.8M
Operating Income
-18792000
-72.7%
-10881000
+4.9%
-11436000
+22.7%
-14796000
+44.7%
-26745000
EBITDA
-18621000
-73.8%
-10713000
+5.0%
-11274000
+22.9%
-14630000
+45.0%
-26580000
Net Income
-18257000
-77.1%
-10310000
+4.5%
-10792000
+22.7%
-13964000
+45.8%
-25746000
EPS (Basic)
$-7.43
-68.9%
$-4.40
+0.0%
$-4.40
+22.7%
$-5.69
+46.3%
$-10.60
EPS (Diluted)
$-7.43
-68.9%
$-4.40
+0.0%
$-4.40
+22.7%
$-5.69
+46.3%
$-10.60
Shares (Diluted)
2.5M
+0.2%
2.5M
+0.0%
2.5M
-0.1%
2.5M
+1.1%
2.4M
aTyr Pharma (ATYR) — Financials